Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;36(1):2449344.
doi: 10.1080/09537104.2024.2449344. Epub 2025 Jan 15.

Transcriptomic and functional characterization of megakaryocytic-derived platelet-like particles: impaired aggregation and prominent anti-tumor effects

Affiliations

Transcriptomic and functional characterization of megakaryocytic-derived platelet-like particles: impaired aggregation and prominent anti-tumor effects

Kaitlin Garofano et al. Platelets. 2025 Dec.

Abstract

Platelet-like particles (PLPs), derived from megakaryocytic cell lines MEG-01 and K-562, are widely used as a surrogate to study platelet formation and function. We demonstrate by RNA-Seq that PLPs are transcriptionally distinct from platelets. Expression of key genes in signaling pathways promoting platelet activation/aggregation, such as the PI3K/AKT, protein kinase A, phospholipase C, and α-adrenergic and GP6 receptor pathways, was missing or under-expressed in PLPs. Functionally, PLPs do not aggregate following epinephrine, collagen, or ADP stimulation. While PLPs aggregated in response to thrombin, they did not display enhanced expression of surface markers P-selectin and activated α2bβ3, in contrast to platelets. We have previously demonstrated that platelets physically couple to MDA-PCa-2b and RC77T/E prostate cancer (PCa) cells via specific ligand-receptor interactions, leading to platelet-stimulated cell invasiveness and apoptotic resistance, and reciprocal cell-induced platelet aggregation. In contrast, PLP interactions with PCa cells inhibited both cell invasion and apoptotic resistance while failing to promote PLP aggregation. Moreover, PLPs reduced platelet-PCa cell interactions and antagonized platelet-stimulated oncogenic effects in PCa cells. RNA-Seq analysis identified candidate ligand-transmembrane protein combinations involved in anti-tumorigenic signaling of PLPs to PCa cells. Antibody neutralization of the TIMP3-MMP15 and VEGFB-FGFR1 signaling axes reversed PLP-mediated anti-invasion and apoptotic sensitization, respectively. In summary, PLPs lack many transcriptomic, molecular and functional features of platelets and possess novel anti-tumorigenic properties. These findings indicate that PLPs may have a potential therapeutic role in targeting and disrupting the oncogenic signaling between platelets and cancer cells, offering a new avenue for anti-cancer strategies.

Keywords: Apoptosis; MDA-PCa-2b cells; RC77T/E cells; cancer biology; cell invasion; functional genomics; platelet; platelet-like particle; prostate cancer.

Plain language summary

What is the context? This study investigates the role of PLPs as substitutes for platelets in cancer biology, focusing on their ability to replicate platelet functions, particularly in stimulating cancer cell oncogenicity. Given the challenges of obtaining blood from volunteers in a timely manner and isolating a pure population of platelets, PLPs were explored as a potentially valuable alternative, though their biology as platelet surrogates remains untested.What is new? A comprehensive comparison of the transcriptome of PLPs compared to platelets.This research is the first to examine whether PLPs can communicate with cancer cells to promote oncogenicity and whether cancer cells can stimulate PLP aggregation. It provides novel insights into the potential of PLPs as a surrogate model in cancer studies.What is the impact? The study demonstrated that PLPs are transcriptionally distinct from platelets, lacking key genes in signaling pathways involved in platelet aggregation and cancer cell stimulation. Functionally, PLPs did not aggregate in response to agonists or cancer cells and instead exhibited anti-oncogenic effects on cancer cells. Moreover, PLPs functionally antagonized platelet-stimulated cancer cell oncogenicity. These findings suggest that PLPs could serve as a therapeutic tool to target and disrupt the oncogenic signaling between platelets and cancer cells.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest with the contents of this article.

References

    1. Li S, Lu Z, Wu S, Chu T, Li B, Qi F, Zhao Y, Nie G. The dynamic role of platelets in cancer progression and their therapeutic implications. Nat Rev Cancer 2024;24:72–87. Epub 20231201. - PubMed
    1. Giannakeas V, Kotsopoulos J, Brooks JD, Cheung MC, Rosella L, Lipscombe L, Akbari MR, Austin PC, Narod SA. Platelet Count and Survival after Cancer. Cancers (Basel) 2022;14. Epub 20220121. - PMC - PubMed
    1. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 2001;98:3352–3357. Epub 2001/03/15. - PMC - PubMed
    1. Egan K, Cooke N, Kenny D. Living in shear: platelets protect cancer cells from shear induced damage. Clin Exp Metastasis 2014;31:697–704. Epub 2014/06/20. - PubMed
    1. Strasenburg W, Jozwicki J, Durslewicz J, Kuffel B, Kulczyk MP, Kowalewski A, Grzanka D, Drewa T, Adamowicz J. Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy. Front Oncol 2022;12:909767. Epub 20220623. - PMC - PubMed

LinkOut - more resources